|
| |
| KLSE: HONGSENG (0041) | MSCM HOLDINGS BERHAD | MAIN : Technology |
| Last Price | Today's Change | Day's Range | Trading Volume |
| 1.23 | 0.00 (0.00%) | 0.00 - 0.00 | 0 |
| Trade this stock for as low as 0.05% brokerage. Find out more. |
Financials
Market Cap: 639 Million
| Latest Audited Result: 31-Mar-2020
| Latest Quarter: 30-Sep-2020 [#2]
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Annual (Unaudited) ( EPS: -1.43, P/E: -85.96 )
| T4Q Result ( EPS: -1.42, P/E: -86.80 )
| Annualized Result ( EPS: 0.55, P/E: 223.76 )
|
Business Performance
Business Performance (By Quarter)
| Trailing 4 Quarters | Trailing 8 Quarters | |||
|---|---|---|---|---|
| Available Quarters | 4 Quarters | 8 Quarters | ||
| Continuous Quarters Of Revenue Growth | 2 / 4 | 50.00% | 2 / 8 | 25.00% |
| Total Positive Profit Years | 1 / 4 | 25.00% | 3 / 8 | 37.50% |
| Continuous Quarters Of Positive Profit | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
| Continuous Quarters Of Profit Growth | 2 / 4 | 50.00% | 2 / 8 | 25.00% |
| Continuous Quarters Of Adjusted EPS Growth | 2 / 4 | 50.00% | 2 / 8 | 25.00% |
| Total Dividend Years | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Dividend | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Adjusted Dps Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Average ROE | -3.17% | -10.04% | ||
| Average Net Profit Margin | -561.30% | -390.84% | ||
Business Performance (By Year)
| Last 5 Financial Years | Last 10 Financial Years | |||
|---|---|---|---|---|
| Available Years | 5 Years | 10 Years | ||
| Continuous Years Of Revenue Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Total Positive Profit Years | 0 / 5 | 0.00% | 3 / 10 | 30.00% |
| Continuous Years Of Positive Profit | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Years Of Profit Growth | 2 / 5 | 40.00% | 2 / 10 | 20.00% |
| Continuous Years Of Adjusted EPS Growth | 2 / 5 | 40.00% | 2 / 10 | 20.00% |
| Total Dividend Years | 0 / 5 | 0.00% | 2 / 10 | 20.00% |
| Continuous Years Of Dividend | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Years Of Dividend Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Years Of Adjusted Dps Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Average ROE | -43.59% | -21.73% | ||
| Average Net Profit Margin | -89.21% | -44.44% | ||
Key Result
Key Result
| T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
|---|---|---|---|---|---|
| Revenue | 2,144 | 2,116 | 4,429 | 30,198 | 21,296 |
| NP to SH | -7,362 | 2,856 | -7,434 | -6,374 | -13,686 |
| Dividend | 0 | - | - | 1,078 | - |
| Adjusted EPS | -1.42 | 0.55 | -1.43 | -1.23 | -2.64 |
| Adjusted DPS | 0.00 | 0.00 | 0.00 | 0.21 | - |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
Growth
Growth (By Quarter)
| LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
|---|---|---|---|---|---|
| Revenue | 0.38% | -59.94% | -68.36% | -1.12% | -59.46% |
| NP to Owner | 143,000.00% | 51.54% | 5.39% | 177.64% | 156.59% |
| Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Adj. EPS | 143,000.02% | 51.54% | 5.39% | 177.64% | 156.59% |
| Adj. DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
Growth (By Year)
| T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -51.59% | -89.93% | -92.90% | -52.22% | -90.06% | -92.99% | -57.86% | -79.20% | -85.33% |
| NP to Owner | 0.97% | 46.21% | -15.49% | 138.42% | 120.87% | 144.80% | 43.13% | 45.68% | -16.62% |
| Dividend | 0.00% | 0.00% | 0.00% | - % | - % | - % | 0.00% | 0.00% | 0.00% |
| Adj. EPS | 0.97% | 46.21% | -15.49% | 138.42% | 120.87% | 144.80% | 43.13% | 45.68% | -16.62% |
| Adj. DPS | 0.00% | 0.00% | 0.00% | - % | - % | - % | 0.00% | 0.00% | 0.00% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
  night_shadow hashimi sure or not can fly? mcm con job jer ni haha. I think next week kot fly after all T 2 T 3 forced to sell then jerung will pick it up 23/10/2020 10:28 AM VinchansoLee This is a super solid company, dealing with all kind of engine related products. Which includes Lorry truck business, Diesel Genset, Marine application engines, engine parts and filtration system and etc. It's like a smaller version of Tan Chong Group Bhd to me. Excellent set up... 23/10/2020 1:55 PM night_shadow @VinchansoLee smaller version of Tan Chong? aiyo Tan Chong also downtrend for the past 5 years already woo huhu 27/10/2020 11:43 AM rote162b2 5 October 2020: HS Bio Supplies Sdn Bhd (Hong Seng’s 51% subsidiary) entered into agreement with RP Integrated Bhd to pursue distributorship of vaccines from Shanghai Fosun Pharmaceutical Group Co. Ltd. (Bursa Announcement) 4 November 2020: Shanghai Fosun Pharmaceutical Group Co. Ltd. to seek approval for BioNTech’s Covid-19 second vaccine known as BNT162b2. (Reuters) 9 November 2020: Pfizer and BioNTech’s BNT162b2 vaccine is 90% effective. 10/11/2020 10:08 AM rote162b2 13 November 2020: China approves Shanghai Fosun Pharmaceutical Group Co. Ltd to run human testing for BioNTech's COVID-19 vaccine BNT162b2. (Reuters) 14/11/2020 3:23 PM roshazli Covid-19 vaccine dampens sentiment on glove counters in morning trade KUALA LUMPUR (Nov 16): Glove stocks were headed lower in Bursa Malaysia's morning trading session today due to the news flow of Covid-19 vaccine progress, which dampened sentiment on the counters. As at the time of writing, glove stocks were among the top losers today. At 11.53am, Hartalega Holdings Bhd, being the second top loser, was down 4.29% or 66 sen at RM14.72, bringing its market capitalisation lower to RM50.54 billion. It saw some 2.78 million shares traded. In the fourth place was Supermax Corp Bhd, which fell 5.24% or 46 sen to RM8.32, with a market value of RM22.72 billion. More than seven months after the World Health Organization (WHO) declared the Covid-19 outbreak in China a “public health emergency of international concern”, the global economy continues to reel from the impact of the virus. Meanwhile, Top Glove Corp Bhd, which bought back 8.94 million or 0.72% of its shares for RM69.9 million in the open market last Friday, dropped 3.98% or 31 sen to RM7.47, valuing the stock at RM61.47 billion. The counter was the seventh biggest loser as at the time of writing. The smaller players were also not spared from the selling pressure. Kossan Rubber Industries Bhd lost 4.2% or 28 sen to RM6.38, Careplus Group Bhd fell 6.58% or 20 sen to RM2.84, and Comfort Gloves Bhd shed 4.71% or 19 sen to RM3.84. The Healthcare Index was dragged down by the glove stocks, declining by 1.75% or 69.68 points to 3,921.47. Last week, Pfizer and its German partner BioNTech announced that their experimental Covid-19 vaccine was more than 90% effective with no serious safety concerns based on initial trial results. They also estimated that they can roll out up to 50 million doses this year for 25 million people and produce 1.3 billion doses in 2021. 16/11/2020 3:47 PM roshazli KUALA LUMPUR (Nov 16): The government has communicated with 10 Covid-19 vaccine producers following a notification by the World Health Organization (WHO) that there are 11 Covid-19 vaccine candidates in phase 3 clinical trial (as of Nov 13). Science, Technology and Innovation Minister Khairy Jamaluddin said communications with eight of the producers was made directly, while the other two was through the Covid-19 Vaccine Global Access Facility (COVAX). He said some of the discussions are in the final stage and an official announcement would be made when everything has been finalised. “The discussion covers aspects of cooperation in various stages of vaccine development such as R&D (research and development), exchange of scientists, fill and finish development (transfer of technology, logistics, cold chain), including the purchase of vaccines (finished products) as a guarantee of access to vaccine supply for the country," he said during the questions for oral answers session in the Dewan Rakyat today. He was responding to a question from Chan Foong Hin (Pakatan Harapan-Kota Kinabalu) who wanted to know whether the ministry had made any order to import vaccines from companies from China, such as Cansino, Sinovac and Sinopharm, or the UK, such as AstraZeneca, and whether the ministry would set the order of priority for Covid-19 vaccination as being done in Indonesia. Khairy said through participation in COVAX, Malaysia would have access to the supply of Covid-19 vaccine of 10% of the country's population and the government was working to get another 60% to meet the national immunisation target for herd immunity to up to 70 per cent of the country's population. The government, he said, was also working to get vaccine access as early as the first or second quarter of next year depending on the approval from the National Pharmaceutical Regulatory Agency (NPRA). He said the NPRA will ensure that a vaccine passes the stipulated strict conditions, covering its safety and effectiveness through data on the clinical trial that was conducted. Meanwhile, on the list of immunisation priorities, Khairy said the Special Committee on Covid-19 Vaccine Supply Access (JKJAV), set up on Oct 14 , had agreed to divide it into three groups, namely the frontliners, involving staff of the Ministry of Health (MoH) and agencies not under the MoH, such as the police, the Malaysian Armed Forces, Immigration Department and others, in the first group. The second is for high-risk groups, such as individuals with co-morbid and seniors citizens, and the third involves other adult population. Details of the groups are being made and the announcement is expected to be made during the first quarter of next year. 16/11/2020 3:47 PM PotentialStock https://www.nst.com.my/amp/business/2020/10/630055/hong-seng-inks-distribution-deal-rpm-chinas-covid-19-vaccine 19/11/2020 12:54 AM roshazli Asian foreign exchange, stocks get vaccine boost as rebound hopes bloom BENGALURU (Dec 3): Emerging Asian currencies and stocks broadly firmed on Thursday, as news that Britain would start vaccinating citizens against the coronavirus next week fanned hopes of a swift global economic rebound next year as the pandemic subsides. Signs of progress in U.S. stimulus talks overnight also supported risk appetite and investors shunned the U.S. dollar in favour of currencies with higher yields and other emerging market assets. Britain on Wednesday became the first western country to approve Pfizer Inc's COVID-19 vaccine, with its chief executive confident that vaccine supply would outpace demand by the end of 2021. "Vaccines have provided a shot in the arm for sentiment thanks to the improving likelihood of a faster and more robust growth recovery," Societe Generale analysts said in a report. Malaysian stocks jumped 0.9% to lead gains in Southeast Asia, while shares in South Korea and Singapore also rose. Indonesian stocks hit a more than nine-month high, but later gave up gains to trade lower after the country's president said he hoped the central bank would take on "a more significant role" in upcoming reforms. Proposals made in recent months to expand Bank Indonesia's mandate have irked investors and analysts and raised doubts about the central bank's independence. Most regional currencies traded higher as the dollar continued to plumb a near two-and-a-half year low. The greenback has been sold-off since last month as market participants pile into riskier holdings amid positive vaccine news and hopes of further stimulus support, and analysts at Goldman Sachs contend this trend may continue. "An integral part of our negative dollar outlook for 2021 is that vaccine development and distribution will lead to coordinated global growth, helping to catalyze portfolio outflows from the U.S. into other markets," they said. "Portfolio flows to more pro-growth sectors, particularly in China and other emerging markets, are likely a key factor behind the dollar's recent depreciation, and we expect that to continue." Philippine stocks added 0.6% after data showed the country's unemployment rate eased in October as coronavirus curbs were gradually lifted, while Thai shares <.SETI > bounced 0.4%. Thai officials on Wednesday announced plans for 43.5 billion baht ($1.44 billion) of additional stimulus to try to boost domestic consumption and revive the tourism-reliant economy, even as global infections continue to rise. Thailand also faces risk from continued political uncertainty and anti-government protests, which have been raging for months. "The protests do not bode well for an already-contracting economy. We see political tensions mounting and lasting into 2021, with no clear solution in sight at this juncture," said Tim Leelahaphan, an economist at Standard Chartered. 03/12/2020 10:07 PM roshazli Fact box: When and which Covid-19 vaccines are likely to be available in Asia BEIJING/TOKYO/SEOUL/MANILA/TAIPEI/JAKARTA/DHAKA/HANOI (Dec 11): Trial data from Pfizer Inc with partner BioNTech SE, Moderna Inc and AstraZeneca Plc has shown their experimental vaccines are effective in preventing novel coronavirus infection. While regulatory processes are underway, few Asian countries expect to receive significant amounts of the vaccines initially. Here are estimated distribution time lines, supply deals announced and clinical trials being held in the region. Australia The country has secured around 140 million doses: 53.8 million from AstraZeneca, 51 million from Novavax Inc, 10 million from Pfizer, and 25.5 million from distribution programme COVAX. It expects delivery of 3.8 million doses of AstraZeneca's vaccine in January and February next year and plans to begin inoculations in March. China China has not announced supply deals with Western drugmakers, which instead have partnered with private companies in the country.AstraZeneca's vaccine may be approved in China by mid-2021 and its Chinese partner Shenzhen Kangtai Biological Products Co Ltd plans annual production capacity of at least 100 million doses by the end of this year. For the Pfizer/BioNTech vaccine, a unit of Shanghai Fosun Pharmaceutical Group Co Ltd plans a Phase II trial. Tibet Rhodiola Pharmaceutical Holding Co is bringing in Russian vaccine candidate Sputnik V and plans early and mid-stage trials in China. China has also approved three vaccine candidates developed by Sinovac Biotech Ltd and state-owned China National Pharmaceutical Group (Sinopharm) for emergency use, and Sinopharm hopes its two candidates will get conditional approval for general use this year. Japan Japan has deals to buy 120 million doses from Pfizer/BioNTech in the first half of next year and 120 million from AstraZeneca - the first 30 million of which will be shipped by March 2021 - and 250 million from Novavax. It is also in talks with Johnson & Johnson and has a deal with Shionogi & Co Ltd. Experts said vaccine makers would need to conduct at least Phase I and II trials in Japan before seeking approval for use. South Korea The country has deals to buy 20 million doses each from AstraZeneca, Pfizer and Moderna and another 4 million doses from Johnson & Johnson's Janssen, enough to cover up to 34 million people.It will procure additional doses for 10 million people through COVAX.Inoculation is likely to start in the second quarter of next year to allow time to observe possible side effects. India The head of the Serum Institute of India, which makes the AstraZeneca vaccine, said on Nov. 23 the positive late-state trial result of the candidate will allow it to seek emergency use approval by year-end, before securing approval for full introduction by February or March. India also expects a government-backed vaccine to be launched as early as February. It is also conducting a late-stage trial of Sputnik V. Taiwan Taiwan aims to secure around 15 million doses initially, both via the COVAX scheme and by direct purchases from manufacturers, and may buy an additional 15 million doses. The government has said it hopes to begin vaccinations in the first quarter next year. Malaysia The Southeast Asian nation has agreed to buy 12.8 million doses of the Pfizer vaccine, becoming the first country in the region to announce a deal with the U.S. drugmaker after some expressed reservations over the need for the ultra-cold storage that the vaccine requires. Pfizer will deliver the first batch of 1 million doses in the first quarter of next year. The Philippines The archipelago announced a deal on Nov. 27 for 2.6 million doses of the AstraZeneca vaccine and is discussing a possible 1 million more, covering about 1% of a population of 108 million people.It is also seeking 20 million to 50 million doses from Sinovac and is in talks with others, including Pfizer.Vaccine makers can seek approval from Philippine regulators even if no clinical trial is conducted in the country. Indonesia Southeast Asia's most populous country has secured 125.5 million doses from Sinovac, 30 million from Novavax, is in talks with AstraZeneca and Pfizer to buy 50 million doses each, and expects to get 16 million from COVAX.Indonesia is testing Sinovac's vaccine and preparing mass vaccination for medical staff and other frontline workers to start as soon as late January. Vietnam A government official said COVAX vaccines would cover only 20% of the population and the country is likely to have a chance to secure separate deals soon, as demand is very high. Bangladesh Bangladesh signed a deal with India's Serum Institute to buy 30 million doses of the AstraZeneca vaccine.It also expects to receive 68 million doses from global vaccine alliance GAVI at a subsidised rate, a senior health ministry official said. 11/12/2020 4:26 PM Combilia Hubella https://www.klsescreener.com/v2/announcements/view/3274899 This agreement was terminated. 13/12/2020 9:45 AM Combilia Hubella Next Vaccine counter to rise may be Tawin. because Tawin is buying over 30% of Royce Pharma. 13/12/2020 9:47 AM FakeSifu https://www.thestar.com.my/business/business-news/2020/12/28/hong-seng-to-acquire-105-acres-in-kedah-rubber-city 28/12/2020 8:43 PM ThePowerOfGlove Hong Seng to buy land in Kedah Ruber City for RM45.74 million to set up nitrile butadiene latex plant https://www.theedgemarkets.com/article/hong-seng-buy-land-kedah-rubber-city-rm4574m-set-nitrile-butadiene-latex-plant 29/12/2020 1:12 AM noelchia92 Found an interesting video I found on Facebook from Xifu.my about Hong Seng. I hope you found this helpful https://www.facebook.com/104014344768624/videos/473270203646163 29/12/2020 9:29 AM noelchia92 Found an interesting video I found on Facebook from Xifu.my about Hong Seng. I hope you found this helpful https://www.facebook.com/104014344768624/videos/473270203646163 29/12/2020 9:50 AM doreenlmy Hong Seng is buying a piece of land in Kedah Rubber City (KRC) for RM45.74mil to build a factory which produces nitrile butadiene late used in the making of nitrile gloves. Xifu.my interviewed the boss recently and he spoke about the Kedah Rubber City....interesting.. https://xifu.my/VideoPlayer.aspx?VID=7e290f57e1264dcfa5d9cd5fa1ece1d5 30/12/2020 12:35 AM anthonytkh In 120k @ 1.26 today Out 120k @ 1.32 today My 1.32 sell order took a long time to be matched 13/01/2021 4:34 PM awesome20 bought on monday at 1.05..thanks "gift idea bursa" telegram channel for this..easy 24% ROI in 3days 13/01/2021 7:38 PM  James Ng https://klse.i3investor.com/blogs/general/2021-01-13-story-h1539322847.jsp [转贴] [Video:浅谈HONG SENG CONSOLIDATED BERHAD, HONGSENG, 0041] - James的股票投资James Share Investing 13/01/2021 9:01 PM newbie8080 If Neogenix can provide more than extraordinary profit during this pandemic, why would the selling shareholder,Neoh Cheu An want to give up his 60% stakes for RM6.5 million to Hong Seng. Something fishy here. 17/01/2021 2:46 PM  |
|
